期刊
WORLD NEUROSURGERY
卷 162, 期 -, 页码 E49-E57出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.wneu.2022.02.043
关键词
CyberKnife; Gamma Knife; Glomus jugulare; Jugular paraganglioma; Linear accelerator; Stereotactic radiosurgery
资金
- Hiromu Matsumoto Scholarship at the John A. Burns School of Medicine in Honor of the Dr. Windsor Cutting Award
- Samuel Goldwyn David Geffen School of Medicine Scholarship
- Gurtin Skull Base Research Fellowship
- David Geffen Medical Scholarship
- UCLA Visionary Ball Fund Grant
- Eli and Edythe Broad UCLA Center of Regenerative Medicine and Stem Cell Research Scholars in Translational Medicine Program Award
- Jason Dessel Memorial Seed Grant
- UCLA Honberger Endowment Brain Tumor Research Seed Grant
- Stop Cancer (U.S.) Research Career Development Award
This meta-analysis evaluated the effectiveness of stereotactic radiosurgery (SRS) as a treatment option for Glomus jugulare tumors (GJTs). The results showed a high tumor control rate and symptomatic improvement rate with SRS, suggesting its suitability as a treatment modality for these tumors. Further studies are needed to explore the potential role of SRS in managing GJTs.
BACKGROUND: Glomus jugulare tumors (GJTs) are benign paragangliomas of the jugular foramen. Traditional management of these tumors involves surgical resection; however, considering the proximity of these tumors to important neurovasculature, stereotactic radiosurgery (SRS) may be an appropriate noninvasive treatment to consider. The aim of this meta-analysis was to evaluate SRS as a treatment option for GJTs. METHODS: An online search using PubMed, Web of Science, Scopus, and Cochrane databases was performed in March 2019 for articles on radiosurgery treatment of GJTs. The screening process followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. RESULTS: The final analysis comprised 23 studies including 460 patients. Average rates of tinnitus, hearing loss, and lower cranial nerve deficit as presenting symptoms were 56% (95% confidence interval [CI], 46%-66%), 56% (95% CI, 44%-68%), and 42% (95% CI, 31%-54%), respectively. Overall clinical status improvement rate after treatment was 47% (95% CI, 37%-57%). Rates of tinnitus, hearing loss, and lower cranial nerve improvement after treatment were 54% (95% CI, 44%-63%), 28% (95% CI, 19%-40%), and 22% (95% CI, 11%-39%), respectively. The mean follow-up time across studies was 47 months (range, 4-268 months). The aggregate tumor control rate at the time of follow-up was 95% (95% CI, 93%-97%). CONCLUSIONS: The tumor control rate of 95% and 47% symptomatic improvement suggest that SRS may be a suitable treatment modality for these hypervascular skull base tumors. Future studies are warranted to further evaluate the potential role of SRS in management of GJTs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据